The FDA approved an expanded age indication for Staar Surgical's EVO/EVO+ Visian Implantable Collamer Lenses, extending eligibility from ages 21-45 to 21-60 years old. This could add nearly 8 million refractive patients to the market. The approval is based on three-year clinical trial data showing strong safety profiles. Despite the positive news, the stock trades 9.8% below its 20-day moving average with bearish technical indicators, though RSI suggests oversold conditions.

STAAR Surgical shares declined as Broadwood Partners, which owns 31% of the company, gained board influence with two new directors joining alongside Christopher Wang of Yunqi Capital. The changes follow the failed merger with Alcon and include the departure of Chair Elizabeth Yeu, with CEO Stephen Farrell remaining until January 31, 2026. The stock is trading below key moving averages with mixed technical signals.

The global LASIK eye surgery market is projected to grow from USD 2.25 billion in 2025 to USD 3.77 billion by 2033, at a CAGR of 6.68%. Growth is driven by rising refractive disorders, AI-enabled surgical innovations, and expanding healthcare infrastructure. However, concerns over long-term safety complications such as corneal thinning and dry eye are limiting adoption. Asia-Pacific is the fastest-growing region, while North America dominates with 44.26% market share.

The global intraocular lens market is projected to grow from USD 5.97 billion in 2025 to USD 9.85 billion by 2033, driven by rising cataract prevalence, aging populations, and advanced lens technologies. However, high costs of premium lenses and limited accessibility in developing regions remain key challenges. North America leads the market with 38.61% share, while Asia Pacific is expected to witness the fastest growth at 7.03% CAGR.

STAAR Surgical announced that shareholders did not approve its merger with Alcon Inc., which was valued at approximately $1.6 billion. The deal will be terminated with no termination fees owed by either party. STAAR will remain a standalone publicly traded company and focus on profitable growth and expanding its EVO ICL technology globally. Major shareholder Broadwood Partners (30.2% stake) and Yunqi Capital Limited (5.1% stake) had opposed the merger.

Top investors of STAAR Surgical, including Yunqi Capital and Broadwood Partners, have rejected Alcon's revised acquisition offer of $30.75 per share, citing a flawed sale process and insufficient valuation.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to recent corporate sales involving STAAR Surgical, Guess?, and Semler Scientific.

Halper Sadeh LLC is investigating potential securities law violations related to the mergers of Staar Surgical and CyberArk Software, encouraging shareholders to explore their legal rights and options.

Halper Sadeh LLC is investigating potential securities law violations related to the mergers of Staar Surgical and CyberArk Software, encouraging shareholders to explore their legal rights and options.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies, focusing on recent merger and acquisition transactions.

Law firm Kaskela Law LLC is investigating the fairness of STAAR Surgical Company's proposed buyout by Alcon at $28.00 per share, which is lower than the company's 52-week high of $38.60.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.